Psoriatic Arthritis | To Observe the Impacts of Anti-Tumor Necrosis Factor (TNF) Effectiveness on Improvement in Work Place and Household Productivity for Patients With Psoriatic Arthritis (PsA)
Psoriatic Arthritis research study
What is the primary objective of this study?
This post marketing observational study is designed to provide the initial data on work impairment of PsA patients in Turkey, as well as changes in work impairment, life quality and clinical response during treatment with anti-TNF agents.
Who is eligible to participate?
Inclusion Criteria: - Actively working, either full-time or part-time - Previous confirmed diagnosis of PsA by a rheumatologist - Patients for whom the physician has initiated PsA treatment with an Anti-TNF in accordance with Turkish Ministry of Health regulations and reimbursement criteria - Able to provide authorization to use and disclose their health related information Exclusion Criteria: - Patients with a history of an allergic reaction or significant sensitivity to anti-TNF agents - Patients with possible follow-up problems during the planned study period or patients who may not be compliant to treatment as evaluated by the investigator/treating physician - Patients participating in any clinical trial of an experimental drug 30 days prior to the baseline visit
Which medical condition, disease, disorder, syndrome, illness, or injury is researched?
Interventions can include giving participants drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available or noninvasive approaches such as surveys, education, and interviews.
Research studies and clinical trials typically have two or more research arms. An arm is a group of people who receive the same treatment in the study.
Participants Receiving Anti-TNF for PsAParticipants who are actively working (full-time or part-time) with rheumatologist-confirmed PsA for which the physician has initiated treatment with an anti-TNF.
Start Date: January 2014
Completed Date: April 2016
Primary Outcome: Work Productivity and Activity Impairment (WPAI) Questionnaire: Mean Percentage of Work Time Missed (Absenteeism) Up to Month 9
Secondary Outcome: Health Assessment Questionnaire Disability Index (HAQ-DI) Score Up to Month 9
Study sponsors, principal investigator, and references
Principal Investigator: Mahmut Gücük, MD
Lead Sponsor: AbbVie